ClinicalTrials.gg
Status unknownNCT04170595Updated Mar 3, 2021

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

A Phase 1/2 interventional study of GB221,2 mg/kg and GB221,6 mg/kg in HER2-positive Breast Cancer, sponsored by Genor Biopharma Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Genor Biopharma Co., Ltd. (part of Edding Genor Group Holdings Limited) · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 years 7 months after the study started (first participant enrolled Mar 2014, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
730th of 1,519
132 · median 120
Started
2014
with 39 others
Phase 1/2
108 of 1,928
61 open now
Registered
563rd of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 730th largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 40 that started in 2014, is one of 108 in phase 1/2, and was the 563rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

A randomized, multicenter, Phase I/IIa clinical study to evaluate the tolerability, safety, efficacy, pharmacokinetics and immunogenicity after single/multiple administration of recombinant anti-HER2 humanized monoclonal antibody for injection for the treatment of HER2-positive breast cancer patients.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For single dose:

Inclusion Criteria:

  1. Aged 18 to 65 years;
  2. Histopathologically confirmed breast cancer;
  3. positive (definition: the immunohistochemistry (IHC) test of pathological samples showed HER-2 +++ or immunohistochemistry (IHC) test showed HER-2 ++ and positive FISH amplification test);
  4. HER2-positive breast cancer patients who have no lesion after surgery and never received anti-HER-2 treatment;
  5. The investigators consider that the subject has recovered from the toxic reactions caused by the previous chemotherapy 4 weeks after the last chemotherapy.
  6. The expected survival is 3 months or longer;
  7. performance status is 0, 1 or 2;
  8. The (LVEF)≥50%;
  9. The major organ function is normal and laboratory tests meet relevant criteria:

    l Hematology test:

    • ≥90 g/L (no blood transfusion within 14 days);
    • ≥1.5×109 /L;
    • ≥100×109 /L; l Hepatic and renal function tests:
    • ≤1.5× (upper limit of normal);
    • and AST≤2.5×ULN;
    • Serum Cr ≤ULN;
  10. Normal coagulation function test;
  11. Voluntarily sign the written form

Exclusion Criteria:

  1. Pregnant or breastfeeding females; or women of who have positive urine pregnancy test; or any subjects who are able to bear or father a child but cannot or are unwilling to adopt medically acceptable effective methods during the study period and within 3 months after the end of the study;
  2. Subjects who have any of the following cardiac conditions:

    • Unstable angina pectoris;
    • Medical history of congestive heart failure;
    • Previous medical history of myocardial infarction, coronary artery bypass grafting or coronary stent implantation;
    • pericardial diseases and valvular heart diseases;
    • Serious uncontrolled arrhythmia;
    • Any other cardiac diseases which may cause safety risks for patients if they are enrolled in this study;
  3. Uncontrolled hypertension (defined as screening systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥110mmHg);
  4. Known , or infection;
  5. Allergic constitution; known allergic to the components of the product;
  6. Have drug abuse history or alcohol addiction history;
  7. Participated in other clinical studies within 4 weeks before the initiation of the study;
  8. Have complicated diseases which may interfere with study participation or evaluation at the discretion of the investigator, e.g., uncontrolled infection, coagulation disorders and other diseases, or the investigators consider that participation in this study may lead to greater risks for patients.

For multiple dose groups:

Inclusion Criteria:

  1. Aged 18 to 65 years;
  2. Histopathologically confirmed breast cancer;
  3. HER-2 positive (definition: the immunohistochemistry (IHC) test of pathological samples showed HER-2 +++ or immunohistochemistry (IHC) test showed HER-2 ++ and positive FISH amplification test);
  4. Patients with breast cancer who failed to respond to previous chemotherapy and no more than three lines, and never received anti-HER-2 treatment(subjects in single dose group who experienced disease progression but meet other inclusion/exclusion criteria can be enrolled);
  5. There is at least one measurable target lesion (based on 1.1 criteria):

    • According to Response Evaluation Criteria in Solid Tumors (RECIST V1.1), the target lesions must be accurately measured in at least one dimension (refer to appendix 5);
    • No radiotherapy for target lesions;
  6. The investigators consider that the subject has recovered from the toxic reactions caused by the previous chemotherapy 4 weeks after the last chemotherapy (subjects who are receiving Xeloda monotherapy and achieve efficacy or stable disease can be enrolled in this study).
  7. The expected survival is 3 months or longer;
  8. ECOG performance status is 0, 1 or 2;
  9. The left ventricular ejection fraction (LVEF)≥50%;
  10. The major organ function is normal and laboratory tests meet relevant criteria:

    l Hematology test:

    • Hb≥90 g/L (no blood transfusion within 14 days);
    • ANC≥1.5×109 /L;
    • PLT≥100×109 /L; l Hepatic and renal function tests:
    • TBIL≤1.5×ULN (upper limit of normal);
    • ALT and AST≤2.5×ULN; if there is any hepatic metastasis, ALT and AST ≤5×ULN;
    • Serum Cr ≤ULN;
  11. Normal coagulation function test;
  12. Voluntarily sign the written informed consent form.

Exclusion Criteria:

  1. Pregnant or breastfeeding females; or women of childbearing potential who have positive urine pregnancy test; or any subjects who are able to bear or father a child but cannot or are unwilling to adopt medically acceptable effective contraceptive methods during the study period and within 3 months after the end of the study;
  2. Subjects with known or suspected : Subjects with evidence indicating signs or symptoms of brain metastasis are not allowed to participate in this study unless such brain metastasis is excluded by CT or MRI. However, subjects whose brain metastasis lesions have been controlled can be enrolled (no progression within at least 4 weeks after radiotherapy and/or no neurological symptom or sign after surgical resection, treatment with dexamethasone or mannitol is not necessary);
  3. Subjects who had disease progression after previous chemotherapy with Xeloda.
  4. Subjects who have any of the following cardiac conditions:

    • Unstable angina pectoris;
    • Medical history of congestive heart failure;
    • Previous medical history of myocardial infarction, coronary artery bypass grafting or coronary stent implantation;
    • Clinically significant pericardial diseases and valvular heart diseases;
    • Serious uncontrolled arrhythmia;
    • Any other cardiac diseases which may cause safety risks for patients if they are enrolled in this study;
  5. Uncontrolled hypertension (defined as screening systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥110mmHg);
  6. Known HIV, HBV or HCV infection;
  7. Allergic constitution; known allergic to the components of the investigational product;
  8. Have drug abuse history or alcohol addiction history;
  9. Participated in other clinical studies within 4 weeks before the initiation of the study;
  10. Have complicated diseases which may interfere with study participation or evaluation at the discretion of the investigator, e.g., uncontrolled infection, coagulation disorders and other diseases, or the investigators consider that participation in this study may lead to greater risks for patients.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    GB221,2mg/kg

    Coprelotamab Injection, 2 mg/kg, Single dose,

    Biological: GB221,2 mg/kg

  • Experimental
    GB221,6mg/kg

    Coprelotamab Injection, 6 mg/kg, Single dose,

    Biological: GB221,6 mg/kg

  • Active comparator
    Herceptin,6mg/kg

    Trastuzumab Injection, 6 mg/kg, Single dose,

    Biological: Herceptin,6 mg/kg

  • Experimental
    GB221,8mg/kg

    Coprelotamab Injection, 8 mg/kg, Single dose,

    Biological: GB221,8mg/kg

  • Experimental
    GB221+ Capecitabine

    Multiple dose groups

    Biological: GB221:2mg/kg and Capecitabi:1000mg/kg

  • Active comparator
    Herceptin+Capecitabine

    Multiple dose groups

    Biological: Herceptin:2mg/kg and Capecitabin:1000mg/kg

Interventions

  • BiologicalGB221,2 mg/kg

    Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

    Also known as: Coprelotamab Injection

  • BiologicalGB221,6 mg/kg

    Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

    Also known as: Coprelotamab Injection

  • BiologicalHerceptin,6 mg/kg

    Drug page: Trastuzumab

    Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

    Also known as: Trastuzumab Injection

  • BiologicalGB221,8mg/kg

    Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes

    Also known as: Coprelotamab Injection

  • BiologicalGB221:2mg/kg and Capecitabi:1000mg/kg

    GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.

  • BiologicalHerceptin:2mg/kg and Capecitabin:1000mg/kg

    Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.

06

What researchers measure

Primary outcomes

  1. maximum tolerated dose,MTD

    To evaluate the efficacy and safety of GB221.

    Time frame: Up to 5 weeks

  2. C max

    C max

    Time frame: Up to 5 weeks

  3. AUC (0- t)

    AUC (0- t)

    Time frame: Up to 5 weeks

  4. AUC (0- ∞ )

    AUC (0- ∞ )

    Time frame: Up to 5 weeks

  5. T max

    T max

    Time frame: Up to 5 weeks

  6. T 1/2

    T 1/2

    Time frame: Up to 5 weeks

  7. CL/F

    CL/F

    Time frame: Up to 5 weeks

  8. V/F

    V/F

    Time frame: Up to 5 weeks

  9. K e

    K e

    Time frame: Up to 5 weeks

Secondary outcomes

  1. Antidrug antibody, ADA

    Antidrug antibody, ADA

    Time frame: Up to 5 weeks

07

Study locations

1 of 1 sites recruiting
  • Affiliated Hospital of Academy of Military Medical Sciences
    Beijing, Beijing 100071, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2014 (actual). Primary completion is estimated for Dec 2021, 93 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 93 months is above that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 20, 2019
StartActual
Mar 28, 2014
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2022
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04170595
Responsible party
Sponsor
First posted
Nov 20, 2019
Start date
Mar 28, 2014
Primary completion
Dec 2021 (estimated)
Completion
Dec 2022 (estimated)
Last update
Mar 3, 2021

Study contacts

Shawn Yu, Master
Contact
shawn.yu@genorbio.com
18600332657
Ze Fei Jiang, Ph.D
principal investigator · Affiliated Hospital of Academy of Military Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion